Itromed-SB 50 Capsule contains Itraconazole 50 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is crucial for ergosterol synthesis, an essential component of fungal cell membranes. This inhibition disrupts membrane integrity, leading to fungal cell death. Itromed-SB 50 Capsule is administered orally and is well-absorbed in the gastrointestinal tract, with bioavailability enhanced when taken with food. The drug is extensively metabolized in the liver via the CYP3A4 pathway and has a half-life of approximately 24-42 hours, allowing for convenient dosing schedules. It is important to monitor liver function during prolonged therapy due to potential hepatotoxicity. Caution is advised when co-administered with drugs metabolized by CYP3A4 to avoid significant drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash. Itromed-SB 50 Capsule should be used under medical supervision, particularly in patients with hepatic impairment or congestive heart failure.